^
Association details:
| Biomarker: | EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature
Published date:
06/10/2021
Excerpt:
A 67-year-old Caucasian female patient...lymph nodes demonstrated adenocarcinoma...she was diagnosed with likely Stage IV NSCLC...After the first cycle of chemotherapy, the patient's tissue genomic testing resulted in EML4-ALK fusion, NFKBIA amplification, and NKX2-1 amplification. Given the ALK fusion result, her regimen was switched to crizotinib...PET-CT 2 months after initiation of crizotinib demonstrated a very good partial response to therapy...Her total PFS after starting crizotinib, including time off therapy after CARC development, was 36.9 months.
DOI:
10.1002/ccr3.4278
